Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Sponsor
Novo Nordisk A/S
Study ID
NCT06283641
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.

Study Details

This is a non-interventional study to evaluate the safety and effectiveness of Saxenda® in obese adults and adolescents in Taiwan. The participants will recieve Saxenda® treatment which is a medicine that doctors can already prescribe. The study will last for about 26 weeks.

Key Dates

Start date
Apr 8, 2024
Status verified
Jan 2026
Primary completion
Jan 13, 2025
Completion
Jan 13, 2025

Study Design

Enrollment
300 participants (actual)

Arms

  • Arm: Saxenda®
    Patients with obesity treated with Saxenda® for weight management in routine clinical practice in Taiwan

Primary Outcome Measure

Incidence of adverse events (AEs) by preferred term (PT) [ Time Frame: From baseline (week 0) to week 26 ]

Related Studies